JP2018500365A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500365A5
JP2018500365A5 JP2017534610A JP2017534610A JP2018500365A5 JP 2018500365 A5 JP2018500365 A5 JP 2018500365A5 JP 2017534610 A JP2017534610 A JP 2017534610A JP 2017534610 A JP2017534610 A JP 2017534610A JP 2018500365 A5 JP2018500365 A5 JP 2018500365A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
compound
formula
agent according
hydroxypropylmethylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2017534610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050820 external-priority patent/WO2016101024A1/en
Publication of JP2018500365A publication Critical patent/JP2018500365A/ja
Publication of JP2018500365A5 publication Critical patent/JP2018500365A5/ja
Priority to JP2021210184A priority Critical patent/JP7475324B2/ja
Revoked legal-status Critical Current

Links

JP2017534610A 2014-12-22 2015-12-21 治療方法 Revoked JP2018500365A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021210184A JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014905194A AU2014905194A0 (en) 2014-12-22 Method of Treatment
AU2014905194 2014-12-22
PCT/AU2015/050820 WO2016101024A1 (en) 2014-12-22 2015-12-21 Method of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021210184A Division JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Publications (2)

Publication Number Publication Date
JP2018500365A JP2018500365A (ja) 2018-01-11
JP2018500365A5 true JP2018500365A5 (cg-RX-API-DMAC7.html) 2019-02-07

Family

ID=56148784

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534610A Revoked JP2018500365A (ja) 2014-12-22 2015-12-21 治療方法
JP2021210184A Active JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021210184A Active JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Country Status (12)

Country Link
US (2) US10493067B2 (cg-RX-API-DMAC7.html)
EP (1) EP3236963B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018500365A (cg-RX-API-DMAC7.html)
KR (1) KR20170098897A (cg-RX-API-DMAC7.html)
CN (1) CN107530337B (cg-RX-API-DMAC7.html)
AU (1) AU2015372434B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201791455A1 (cg-RX-API-DMAC7.html)
IL (1) IL253028B (cg-RX-API-DMAC7.html)
MX (1) MX2017008248A (cg-RX-API-DMAC7.html)
SG (1) SG11201704980XA (cg-RX-API-DMAC7.html)
WO (1) WO2016101024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
EP4259138A4 (en) * 2020-12-10 2024-11-06 Imbria Pharmaceuticals, Inc. METHODS OF TREATING CARDIAC DISORDERS USING MODIFIED FORMS OF TRIMETAZIDINE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297360A (en) 1980-03-28 1981-10-27 Sterling Drug Inc. 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use
NZ195564A (en) 1979-11-26 1983-09-30 Sterling Drug Inc 5-pyridinyl-2(1h)-pyridinones pharmaceutical compositions intermediate pyridine compounds
US4313951A (en) 1979-11-26 1982-02-02 Sterling Drug Inc. 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5213811A (en) 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
SK279684B6 (sk) 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
KR100548925B1 (ko) 2002-10-23 2006-02-02 한미약품 주식회사 약물의 경구투여용 서방성 조성물
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
CN103608662B (zh) * 2011-06-29 2016-09-28 京都府公立大学法人 肿瘤部位的识别装置以及识别方法
US10137093B2 (en) * 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
WO2013116194A2 (en) * 2012-01-30 2013-08-08 O'connell Timothy D Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP4991072B2 (ja) 時限拍動性薬物送達システム
US20140072624A1 (en) Unit dose form for oral administration
JP5911969B2 (ja) 心臓血管障害の治療方法
JP2019522024A5 (cg-RX-API-DMAC7.html)
MX2008014296A (es) Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP2014508812A5 (cg-RX-API-DMAC7.html)
JP2016504384A5 (cg-RX-API-DMAC7.html)
JP2020523335A5 (cg-RX-API-DMAC7.html)
JPWO2013147134A1 (ja) ミラベグロン含有医薬組成物
JP2017505822A5 (cg-RX-API-DMAC7.html)
CN115038432A (zh) 水溶性活性药物成分的控制释放制粒
KR20070046152A (ko) 미코페놀산 또는 미코페놀산나트륨을 포함하는 제약다중미립자 조성물 및 라파마이신과의 조합 조성물
JP2009513713A5 (cg-RX-API-DMAC7.html)
JP2004518734A (ja) カルベジロールの新規処方
JP2017531044A5 (cg-RX-API-DMAC7.html)
TW201545745A (zh) 阿利沙坦酯固體分散體及藥物組合物
JP2020525436A5 (cg-RX-API-DMAC7.html)
JP2016525568A (ja) フィンゴリモドの医薬組成物
JP2009506978A5 (cg-RX-API-DMAC7.html)
TW200911303A (en) Powders for reconstitution
CN103381268B (zh) 包含质子泵抑制剂的固体药物组合物
JP2019509309A5 (cg-RX-API-DMAC7.html)
WO2012010944A2 (en) Multiple unit tablet composition